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Understanding the mechanism by which alpha-lipoic acid supplementation has a protective effect upon nonalcoholic fatty liver disease in vivo and in vitro
may lead to targets for preventing hepatic steatosis. Male C57BL/6J mice were fed a normal diet, high-fat diet or high-fat diet supplemented with alpha-lipoic
acid for 24 weeks. HepG2 cells were incubated with normal medium, palmitate or alpha-lipoic acid. The lipid-lowering effects were measured. The protein
expression and distribution were analyzed by Western blot, immunoprecipitation and immunofluorescence, respectively. We found that alpha-lipoic acid
enhanced sirtuin 1 deacetylase activity through liver kinase B1 and stimulated AMP-activated protein kinase. By activating the sirtuin 1/liver kinase B1/AMP-
activated protein kinase pathway, the translocation of sterol regulatory element-binding protein-1 into the nucleus and forkhead box O1 into the cytoplasm was
prevented. Alpha-lipoic acid increased adipose triacylglycerol lipase expression and decreased fatty acid synthase abundance. In in vivo and in vitro studies,
alpha-lipoic acid also increased nuclear NF-E2-related factor 2 levels and downstream target amounts via the sirtuin 1 pathway. Alpha-lipoic acid eventually
reduced intrahepatic and serum triglyceride content. The protective effects of alpha-lipoic acid on hepatic steatosis appear to be associated with the transcription
factors sterol regulatory element-binding protein-1, forkhead box O1 and NF-E2-related factor 2.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).Keywords: Alpha-lipoic acid; FoxO1; Nonalcoholic fatty liver disease; Nrf2; SIRT1; SREBP-1
1. Introduction animal models [2]. Therapeutic options targeting hepatic lipidNonalcoholic fatty liver disease (NAFLD), characterized by
excessive triglyceride (TG) accumulation in the liver, is becoming
increasingly prevalent in Asian-Pacific regions due to Westernization
[1]. The central role of lipid accumulation in the pathogenesis of
NAFLD has been confirmed in many clinical correlation studies andAbbreviations: ACC, acetyl-CoA carboxylase; ALA, alpha-lipoic acid; ALT, al
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Sirtuin 1 (SIRT1) and AMP-activated protein kinase (AMPK) are
known fuel-sensingmolecules thatmodulate lipidmetabolism [3]. AMPK
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Fig. 1. ALAactivates SIRT1/LKB1pathway inHepG2cells. (A) Thedose–response effect ofALAonSIRT1deacetylase activity.HepG2 cellswere treatedwith0, 50, 125, 250and500 μMALA, or 0, 10,
25, 50 and 100 μMresveratrol used as a positive control for 24 h. Data are presented asmean±S.E.M. (n=5). *Pb.05, **Pb.01 vs. control (0 μMALA);#Pb.05,##Pb.01 vs. control (0 μMresveratrol).
(B) Intracellular NAD+/NADH ratio. HepG2 cellswere treatedwith 0 (control), 250, 500 and 1000 μMALA for 24 h. Data are presented asmean±S.E.M. (n=6). *Pb.05, **Pb.01 vs. control (0 μmol
ALA). HepG2 cellswere transfectedwith SIRT1siRNA or scramble siRNA for 24 h after incubationwith ALA (250 μM, 6 h). (C) IP of acetylated liver kinase B1 (LKB1). *Pb.05 vs. control (untreated
HepG2 cells); #Pb.05 vs. ALA group; ΔPb.05 vs. ALA+scramble siRNA group. (D) COIP of SIRT1 and LKB1. Nonspecific IgG was used as control.
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represents an upstream regulator in the LKB1/AMPK signaling axis [3].
Activation of SIRT1/AMPK signaling plays a central role in regulating
hepatic fatty acid metabolism [5]. It abrogates ectopic fat accumulation
by facilitating fatty acid oxidation and curbing the de novo fatty acid
synthesis largely through deacetylation and phosphorylation, respec-
tively, of transcription factors or coactivators, such as p53, forkhead
box O (FoxO), nuclear factor-κB (NF-κB), peroxisome proliferator-
activated receptorγcoactivator1α (PGC-α) and sterol regulatory element-
binding protein 1 (SREBP-1) [6,7].
The transcription factor FoxO1 is regulated by dephosphorylation or
deacetylation that causes its nuclear translocation to induce transcription
of the rate-limiting enzymes of lipolysis, such as adipose triglyceride
lipase (ATGL) [8]. In lipid metabolism, SREBP-1 up-regulates the
expression of de novo lipogenesis via fatty acid synthase (FAS) [9].Fig. 2. ALA suppresses intracellular accumulation of lipids through the SIRT1/LKB1/AMPK signa
250, 500 and 1000 μMALA for 6 h. Protein expression of AMPK, p-AMPK, ACC, p-ACC, FAS and
contents. HepG2 cells were treated with 125 μMPA and different concentrations of ALA for 12 h
of AMPK inhibitor (CC, 20 μM, 0.5 h), SIRT1 inhibitor (NA, 10 mM, 12 h) and AMPK activat
contents in the presence or absence of different activators and inhibitors. (E) HepG2 cells we
(250 μM, 6 h). (F) Measurement of intracellular triacylglycerol in the presence or absence of SI
cells); #Pb.05, ##Pb.01 vs. PA group; ΔPb.05 vs. PA+ALA group.SIRT1/AMPK signaling is intimately associated with the activation or
inactivation of FoxO1 and SREBP-1 and therefore represents attractive
targets in the development of therapies to repress hepatic steatosis.
Several lines of evidence suggest that chronic oxidative stress plays an
important role in the progression of fatty liver due to a close link between
dysregulated lipid homeostasis and oxidative stress [10]. The transcrip-
tion factor NF-E2-related factors 2 (Nrf2) plays a central role in the
defense against oxidative stress. Upon oxidative insults, Nrf2 translocates
to the nucleus where it interacts with antioxidant response element
(ARE) to mediate the transcription of its target genes, such as
hemeoxygenase-1 (HO-1), superoxide dismutase (SOD), glutathione
peroxidase and catalase [11]. The transcription of these genes enhances
cellular resistance against oxidative stress. Previous studies have shown
that Nrf2 plays an important role in the protection of hepatocytes from
NAFLD [12]. SIRT1 is also known tomarkedly protect cells from oxidativeling pathway in HepG2 cells. (A) HepG2 cells were treated with 0 (control, C), 50, 125,
ATGL was determined byWestern blot. (B) Measurement of intracellular triacylglycerol
. (C) Effect of ALA (250 μM, 6 h) on protein expression levels in the presence or absence
or (AICAR, 2 mM, 1 h), respectively. (D) Measurement of intracellular triacylglycerol
re transfected with SIRT1siRNA or scramble siRNA for 24 h after incubation with ALA
RT1 siRNA. All data are presented as mean±S.E.M. (n=6). *Pb.05 vs. control (untreated
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Fig. 3. ALA causes redistribution of transcription factors FoxO1 and SREBP-1 via the SIRT1/LKB1/AMPK signaling pathway. (A and B) HepG2 cells were treated with 125 μM PA and
250 μM ALA for 12 h. Starvation: HepG2 was incubated with serum-free medium. FoxO1 and SREBP-1 protein expression and distribution were determined by immunofluorescence
staining (magnification, 400×). Green: FITC; blue: DAPI. (C) HepG2 cells were treated with 0 (control, C), 50, 125, 250, 500 and 1000 μM ALA for 12 h. *Pb.05, #Pb.05 vs. control
(untreated cells). (D) Effect of ALA (250 μM, 6 h) on FoxO1 and SREBP-1 phosphorylation levels in the presence or absence of AMPK inhibitor (CC, 20 μM, 0.5 h), SIRT1 inhibitor
(NA, 10 mM, 24 h) and AMPK activator (AICAR, 2 mM, 1 h), respectively. *Pb.05, #Pb.05 vs. ALA group.
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stress [14], it might be interesting to explore the synergistic effect of
SIRT1/LKB1/AMPK signaling and Nrf2 in NAFLD.
Alpha-Lipoic acid (ALA), a naturallyoccurringdithiol compound, plays
an essential role in mitochondrial bioenergetics. It has gained consider-
able attention as an antioxidant in managing diabetic complications and
NAFLD [15,16]. Multiple studies have described ALA's functions in lipid
metabolism. For instance, it was shown that ALA activates both SIRT1 and
AMPK and leads to lipid-lowering effects in a skeletal diseasemodel [17],
and ALA inhibits NF-κB and activates AMPK in skeletal muscles, which
leads to severalmetabolic consequences [18,19]. Liverdamage inducedby
n-6 polyunsaturated fatty acids including development of a fatty liver,
fibrosis, inflammation and apoptosis in the liver of young rats was
reduced by ALA injection [20]. In addition, ALA dephosphorylated FoxO1
and reversed the nuclear exclusion of FoxO liver cells [21]. The complex
molecular network involved in NAFLD may represent a potential
therapeutic target for the treatment and prevention of hepatic steatosis
and its progression to steatohepatitis [22]. This study aimed to assess the
dual effect of ALA in regulating both the energy metabolism and redox
system. We then assess whether ALA has an effect on Nrf2, FoxO1 and
SREBP-1 activities via the SIRT1/LKB1/AMPK pathway and controls
lipogenesis protein expression. In addition, we investigated whether
ALA is potentially effective against NAFLD and can improve hepatic
steatosis by eliminating dyslipidemia in the liver. Thus, we hope to reveal
for the first time the close connections between oxidative stress and lipid
metabolism of liver cells through the interactions between the oxidative
stress-related molecule Nrf2 and the energy metabolism-related
molecule SIRT1.
2. Materials and methods
2.1. Animals and grouping
Male C57BL/6J mice (6-week-old; body weight: 22–24 g) were purchased from
Beijing Vital River Biological Co., Ltd. (China) and housed in standard cage conditions at
a constant temperature (22±1°C) and a 13:11-h light/dark cycle. All mice were
allowed ad libitum access to normal diet and water for 2 weeks before dividing into
four groups (n=8): normal diet (ND) (10% energy from fat; D12450B; Research Diets,
New Brunswick, NJ, USA), high-fat diet (HFD) (60% energy from fat; D12492; Research
Diets, USA) and HFD plus ALA (100 mg/kg or 200 mg/kg). These doses of ALA were
selected to be similar to previous studies [17]. After 24 weeks of treatment, blood
samples were collected after the eyeballs of the mice were extracted for serum
preparation by centrifugation at 2000×g for 10 min at 4°C. The liver tissues were
harvested in liquid nitrogen and stored at−80°C. All animal studies were approved by
the Animal Research Committee of Ningxia Medical University, Yinchuan, China.
2.2. Biochemical analyses
Levels of serum biochemistry markers, including TG, total cholesterol (TC),
aspartate aminotransferase (AST), alanine aminotransferase (ALT), high-density
lipoprotein (HDL), low-density lipoprotein (LDL) and nonesterified fatty acids
(NEFAs) were determined using a Biochem-Immuno autoanalyser (Brea, CA, USA).
Serum glutathione (GSH)/glutathione disulfide (GSSG) was measured using Enzymatic
Colorimetric Assay (BIOXYTECH, Portland, OR, USA).
2.3. Detection of intracellular reactive oxygen species (ROS) generation
For the detection of hepatic superoxide production, an oxidative fluorescent dye
dihydroethidium (DHE) was used to evaluate the in situ production of superoxides. The
10 μm-thick liver frozen sections were incubated for 1 h with 50 μM DHE (Beyotime,
Shanghai, China). Fluorescent signals were scanned using a fluorescence microscopy
(Olympus IX71, Tokyo, Japan).
2.4. Cell culture and treatment
The human hepatocellular carcinoma (HepG2) cell line was obtained from the
Chinese Academy of Medical Sciences tumor cell libraries (Beijing, China) and cultured
in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum (GIBCO,
Gran Island, NY, USA) at 37°C and 5% CO2. HepG2 cells were treated with AMPK
inhibitor (CC, 20 μM, 0.5 h), SIRT1 inhibitor (NA, 10 mM, 12 or 24 h), and AMPK
activator (AICAR, 2 mM, 1 h) purchased from (Calbiochem-Novabiochem, San Diego,
CA, USA), and palmitate (PA, 125 μM, 12 h) and ALA (250 μM, 6 or 12 h) provided bySigma-Aldrich (St. Louis, MO, USA). The dose of ALA was selected to be similar to that
used in previous studies [21].
2.5. Western blot
Total protein was extracted with Total Protein Extraction Kit (Applygen
Technologies Inc, Beijing, China), and nuclear and cytosolic fractions were collected
using a nuclear protein extraction kit (Pierce, Nashville, TN, USA) [23], according to the
instructions of themanufacturers. HepG2 cell lysates were prepared using a lysis buffer
containing 50 mM Tris–HCl (pH 7.5), 1 mM EDTA, 1%Triton, protease and phosphatase
inhibitors, 0.1 mM PMSF, 1 μg/ml leupeptin. Lysates were centrifuged at 10,000×g for
10 min at 4°C. Protein concentration was measured using BCA kit (Pierce). Fifty
micrograms of protein was loaded onto 8% or 10% sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene
difluoride membranes (Pall Corporation, Port Washington, NY, USA). The membranes
were incubated with 5% skimmed milk for 1 h at room temperature. Immunoblots
were obtained using antibodies against the following proteins: AMPK (pThr172),
AMPK, acetyl-CoA carboxylase (ACC) (pSer79), ACC, LKB1, HO-1, and acetyl-lysine
(Cell Signaling Technology, Danvers, MA, USA); FAS and Lamin B (Abcam, Cambridge,
MA, USA); SREBP-1 (pSer372), SREBP-1, SIRT1, ATGL, FoxO1 (pSer256), FoxO1, Nrf2,
SOD-2, catalase and beta-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Western blots were exposed using SuperSignal West Femto Maximum Sensitivity
Substrate (Thermo Scientific, Waltham, MA, USA). Film images were scanned by Epson
Perfection V33 (China), and signals were quantified with the Image Pro-Plus 6.0
software (Media Cybernetics, Rockville, MD, USA).
2.6. Immunoprecipitation
For each immunoprecipitation (IP) or co-immunoprecipitation (COIP), 1 mg or
100–500 μg protein was used. Samples were incubated with 20 μl Protein A-G (Santa
Cruz Biotechnology) and 1–2 μg primary antibodies [anti-rabbit-SIRT1 antibody (Santa
Cruz Biotechnology) and anti-rabbit-LKB1 antibody (Cell Signaling Technology)] for
1–2 h at 4°C under constant shaking. Nonspecific IgG (Santa Cruz Biotechnology) was
used as a control. The immunoprecipitates were washed 3–4 times with cold
phosphate-buffered saline (PBS), and the mixture boiled with SDS sample buffer.
Immunoprecipitates were separated on a 10% SDS-PAGE followed by immunoblotting
against antibody.
2.7. SIRT1 small interfering RNA and transfection
Predesigned human SIRT1 siRNA (sc-40986) and control scramble siRNA
(sc-37007) were purchased from Santa Cruz Biotechnology. HepG2 (2×105 cells/well)
cells were seeded in 6-well plates and allowed to adhere overnight. Then, 1 μg SIRT1
siRNA and 1 μg scramble siRNA were transfected into cells using Vigofect (Vigorous
Biotechnology, Beijing, China) according to the manufacturer's instruction. HepG2 cells
were transfected for 24 h after incubation with ALA (250 μM, 6 h).
2.8. NAD+/NADH assay
The NAD+/NADH ratio of HepG2 cells or liver tissues was measured using the
NAD+/NADH Quantification Kit (BioVision Inc, Milpitas, CA, USA) according to the
manufacturer's instruction.
2.9. Measurement of SIRT1 deacetylase activity
SIRT1 deacetylase activity was determined with the SIRT1 Fluorometric Drug
Discovery Kit (Enzo Life Sciences, AG, Lausen, Switzerland) according to the
manufacturer's instruction. Resveratrol (Sigma-Aldrich) was used as a SIRT1 activator.
2.10. Measurement of HepG2 intracellular triacylglycerol
Intracellular triacylglycerol was measured with the Triacylglyceride Assay Kit
(Applygen Technologies Inc), according to the manufacturer's instruction.
2.11. Histological analysis and immunohistochemical staining
Liver tissues were fixed in 4% paraformaldehyde for 24 h, embedded in paraffin,
cut into 5–7 μm-thick sections, and stained with hematoxylin and eosin (H&E) or Oil
Red to observe the lipid droplets in liver tissues. Steatosis and inflammation were used
to assess pathological standard. The severity of steatosis was graded from 1 to 3
according to the percentage of cells with lipid droplets (1, 10%–33%; 2, 33%–66%; and 3,
N66%). The intensity of inflammation was ranked as 1 (mild), 2 (moderate), and 3
(severe) [24]. For immunohistochemistry, liver sections were stained with Nrf2 or
SOD-2 antibodies [12].
2.12. Immunofluorescence staining
HepG2 cells (5×103 cells/well) were seeded on glass coverslips and incubated for
12 h. The cells were fixed in 4% paraformaldehyde for 10 min at room temperature and
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Fig. 5. ALA ameliorates hepatic lipid metabolism in HFD-induced hepatic steatosis mouse model. (A) Effect of ALA (100 mg/kg or 200 mg/kg) on gross contour of the whole body and
visceral fat. (B) Effects of ALA (100 mg/kg or 200 mg/kg) on body weight changes. (C) Effect of ALA (100 mg/kg or 200 mg/kg) on fresh liver weight and hepatic triacylglycerol (TG)
content. (D) Representative photomicrographs of hepatic steatosis and inflammation after H&E staining. Steatosis and inflammation scores were used to assess pathology. *Pb.05 vs.
ND-fed group. Lipid droplets in liver tissues were determined by Oil Red O staining. (E) Effects of ALA (100 mg/kg or 200 mg/kg) on SIRT1, p-AMPK, p-ACC, p-Foxo1, p-SREBP1, ATGL
and FAS protein expressions. All data are presented as mean±S.E.M. (n=8). *Pb.05 vs. ND-fed group, #Pb.05 vs. HFD-fed group.
Fig. 4. ALA activates transcription factor Nrf2 depending on the SIRT1/LKB1/AMPK signaling pathway in vitro and in vivo. (A) Effect of SIRT1 inhibitor (NA, 10 mM, 12 h) and ALA
(250 μM, 6 h) on SOD2, CAT, HO-1 and Nrf2 expressions in HepG2 cells. (B) Effect of SIRT1 siRNA (24 h) and ALA (250 μM, 6 h) on antioxidative protein and Nrf2 protein expression in
HepG2 cells. (C) Effect of ALA (100 mg/kg or 200 mg/kg) on antioxidative protein and Nrf2 protein expression in HFD-induced hepatic steatosis mouse model. (D) Effect of ALA
(100 mg/kg or 200 mg/kg) on the distribution of Nrf2, SOD2 and ROS in vivo. Nrf2 and SOD2 distribution was determined by immunohistochemistry. (E) Effect of ALA (100 mg/kg or
200 mg/kg) on serum GSH/GSSG ratio in vivo. Data are presented as mean±S.E.M. (n=8). *Pb.05 vs. ND-fed group, #Pb.05 vs. HFD-fed group.
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antibodies and fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit IgG as
secondary antibody. The nuclei were stained with 4′,6-diamidino-2-phenylindole
(DAPI) (5 mg/ml) (Beyotime) for 5 min in the dark. Finally, the coverslips were
observed under a fluorescence microscope (Olympus IX71).
2.13. Statistical analysis
Data are presented as mean±standard error of the mean (S.E.M.). The SPSS 13.0
software (SPSS Inc, Chicago, IL, USA) was used to perform one-way analysis of variance
with Student–Newman–Keuls test for post hoc analysis for multiple groups or unpaired
t test for two groups. P value b.05 was considered statistically significant.
3. Results
3.1. ALA regulates hepatocyte lipid metabolism and decreases palmitate-
induced hepatic cellular triacylglycerol accumulation via the SIRT1/
LKB1/AMPK signaling pathway
To test whether ALA increases SIRT1 deacetylase activity in the
liver, we first determined ALA-stimulated deacetylation of a peptide
comprising amino acids Arg-His-Lys-Lys(Ac) 379–382 of human p53
[25]. The results showed that incubation with ALA (50 μM)
significantly increased SIRT1 activity (Fig. 1A, Pb.05 or Pb.01). Since
SIRT1 is an NAD+-dependent enzyme that acts as a metabolic sensor
for NAD+ [25], we next measured the NAD+/NADH ratio in HepG2
cells. Treatment of cells with ALA significantly increased the NAD+/
NADH ratio in HepG2 cells (Fig. 1B, Pb.05 or Pb.01). Treatment with
ALA increased SIRT1 activity in HepG2 cells (Fig. 1A); the increase in
the NAD+/NADH ratio may have resulted in increased SIRT1 activity.
The exact mechanism underlying ALA-stimulated AMPK activation
remains to be clarified. To date, two upstream AMPK kinases
(AMPKK) have been identified: LKB1 and CaMKK [26]. LKB1 likely
controls most of the AMPK activation in a majority of tissues. To
determine whether ALA-mediated SIRT1 activation regulated LKB1
deacetylation, the acetylation level of LKB1 was measured by IP. As
shown in Fig. 1C, ALA significantly reduced LKB1 acetylation (Pb.05),
when the levels of acetylation were normalized to protein input. We
also found that SIRT1-LKB1 was coimmunoprecipitated from cells
(Fig. 1D). The findings confirmed the interaction between SIRT1 and
LKB1 following ALA treatment of HepG2 cells.
These data supported the notion that ALA activated SIRT1 and
regulated the AMPK signaling pathway through LKB1 deacetylation in
the liver. The SIRT1/LKB1/AMPK signaling pathway plays a key role in
the ALA regulation of hepatocyte lipid metabolism [27].
To investigate whether ALA improved AMPK signaling pathway,
we assessed the effects of ALA on phosphorylation of AMPK and ACC.
We found that ALA increased phosphorylation of AMPK and ACC in
HepG2 cells in a dose-dependent fashion (Fig. 2A).
With increased ALA concentration, triacylglycerol accumulation in
palmitate environment significantly decreased (Fig. 2B, Pb.05 or
Pb.01). We examined the effects of SIRT1 inhibitor (nicotinamide;
NA), AMPK inhibitor (compound c; CC) and AMPK activator (5-
aminoimidazole-4-carboxamide riboside; AICAR) on phosphorylation
of AMPK and ACC. As shown in Fig. 2C, ALA increased expression of p-
AMPK and p-ACC in the AIACR group, but a decrease was observed in
the CC group. In addition, p-AMPK and p-ACC levels were reduced by
NA, confirming that SIRT1 acts upstream of AMPK. The ALA and ALA
+AICAR groups showed decreased triacylglycerol accumulation in
the presence of palmitate (Fig. 2D, Pb.05). Specifically the CC and NA
groups increased triacylglycerol accumulation in HepG2 cells. To
further determine the role of SIRT1 in regulating AMPK activation,
SIRT1 siRNA was transfected to test whether p-AMPK production was
reduced. Our data indicated that SIRT1 knockdown significantly
decreased phosphorylation of AMPK and ACC (Fig. 2E). Accordingly,
SIRT1 siRNA altered FAS and ATGL production (Fig. 2E). However,
SIRT1 knockdown failed to attenuate palmitate-induced triacylglyc-erol accumulation in cells (Fig. 2F, Pb.05). These results support the
notion that ALA mediates lipid metabolism through the SIRT1/LKB1/
AMPK signaling pathway [28].
3.2. ALA causes distribution of FoxO1 and SREBP-1 through SIRT1/LKB1/
AMPK signaling
ALA decreases p-FoxO1 expression levels and reinforces FoxO1
activities, and mediates the downstream molecular targets of ATGL
activity [29]. As demonstrated by immunofluorescence (Fig. 3A),
FoxO1 was found mainly in the nuclei of untreated cells. ALA treated
cells showed apparently exclusive nuclear expression of p-FoxO1.
Upon treatment with palmitate, FoxO1 mostly translocated into the
cytoplasm. As shown in Fig. 3A, nuclear translocation of p-FoxO1 was
very obvious in the ALA alone and ALA+palmitic acid groups
compared to the palmitic acid alone stimulation group. At increasing
concentrations of ALA, p-FoxO1 expression decreased also suggesting
migration of FoxO1 into the nucleus (Fig. 3C, Pb.05).
The ALA induced nuclear translocation of FoxO1 was reversed by
pretreatment with NA (Fig. 3D), confirming the ALA-mediated
nuclear localization of FoxO1 occurred via SIRT1/LKB1/AMPK signal-
ing. The phosphorylation of FoxO1 was increased by SIRT1 and AMPK
inhibitors (Fig. 3D) compared to the ALA-treated cells (Pb.05),
suggesting that the ALA-mediated signal transduction pathway is
activated via SIRT1/AMPK down to FoxO1, leading to increased
expression of ATGL but treatment with inhibitors and ALA together
reduced the increase.
SREBP-1 is a membrane-binding protein located on the surface of
the endoplasmic reticulum membrane that controls lipid metabo-
lism-related enzymes (FAS) [30]. To determine the influence of ALA
on the subcellular localization of SREBP-1, cells were treated with ALA
in the presence or absence of CC, NA or AICAR. The SREBP-1 protein
was mainly found in the cytoplasm of ALA-treated cells (Fig. 3B). As
shown in Fig. 3C, ALA caused significant increases in p-SREBP-1 levels
(Pb.05). Interestingly, the phosphorylation of SREBP-1 caused by ALA
was reversed by CC or NA (Fig. 3D, Pb.05).These findings suggested
that ALA might repress the transcription of genes involved in lipid
synthesis by preventing the entry of SREBP-1 into the nucleus
through SIRT1/LKB1/AMPK signaling.
3.3. ALA significantly activated Nrf2/ARE signaling
Nrf2 is an important endogenous antioxidant mediator. When
exposed to oxidative stress, cells exhibit adaptive activation of the Nrf2/
ARE pathway to relieve cell damage [31]. When cells were pretreated
with NA, and then treated with ALA, SIRT1, nuclear Nrf2, SOD, catalase
and HO-1 expressionswere decreased. By contrast, the total Nrf2 levels
displayed no overt changes (Fig. 4A). SIRT1 knockdown also resulted in
decreasedprotein expression (Fig. 4B). ALA (100 mg/kg or 200 mg/kg)-
treated group also showed increased expression of Nrf2 signaling
molecules compared with the HFD group (Fig. 4C). Immunohistochem-
ical staining results also revealed elevated expression of Nrf2 and SOD2,
in agreement with Western blot data (Fig. 4D).
Compared with the HFD group, ALA (100 mg/kg or 200 mg/kg)
significantly increased the level of GSH/GSSG (Fig. 4E, Pb.05).
3.4. ALA ameliorates lipid metabolic function and lipid accumulation in
HFD-induced NAFLD mice
C57BL/6J mice, divided into four groups, were fed an HFD for
24 weeks to induce NAFLD followed by daily administration of ALA.
Then, the effects of ALA on hepatic lipid accumulation in long-term
HFD-fed mice were assessed. Administration of ALA markedly
reduced visceral fat mass in mice (Fig. 5A). In addition, ALA treatment
inhibited the appetite and caused a dramatic weight loss (Fig. 5B, all
Table 1
Variables associated with lipid metabolism after 24-week HFD treatment.
Variables ND HFD HFD+ALA (100 mg/kg) HFD+ALA (200 mg/kg)
Body weight (g) 36.65±2.00 48.76±2.83 ⁎ 39.40±3.89# 42.45±2.84△
Perirenal fat (g) 0.55±0.12 1.17±0.19 ⁎ 0.77±0.31# 0.98±0.16
AST (U/I) 262.66±30.56 312.00±30.80 ⁎ 243.00±31.50# 218.66±22.19△
ALT (U/I) 74.96±30.43 161.80±13.50 ⁎⁎ 56.40±14.93## 101.16±30.39△
Triacylglycerol (mmol/l) 0.87±0.10 1.74±0.22 ⁎ 0.86±0.11# 1.48±0.17△
Cholesterol (mmol/l) 3.57±0.20 5.35±0.93 ⁎ 4.10±0.38# 5.53±1.61
HDL (mmol/l) 6.91±0.06 3.15±0.29 ⁎ 4.26±0.76# 3.16±0.24
LDL (mmol/l) 0.23±0.10 0.54±0.10 ⁎ 0.13±0.11# 0.31±0.06△
NEFA (μmol/l) 144.48±40.34 235.98±78.43 ⁎⁎ 158.50±43.50## 175.54±59.28△
Plasma glucose (mmol/l) 5.06±0.56 8.97±0.90 ⁎ 5.79±0.35# 8.21±0.55
Note: Data are shown as mean±S.E.M. (n=8).
⁎ Pb.05 vs. ND-fed group.
⁎⁎ Pb.01 vs. ND-fed group.
# Pb.05 vs. HFD-fed group.
## Pb.01 vs. HFD-fed group.
△ Pb.05 vs. HFD-fed group.
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(Fig. 5C), the hepatic triacylglycerol content showed a significant
difference (Fig. 5C, Pb.05). Interestingly, lipid droplets as detected by
Oil Red O staining were markedly reduced in the liver after ALA
treatment (Fig. 5D).
Importantly, HFD-induced hepatic steatosis was significantly
reduced in the ALA-treated group, as illustrated by the decrease in
the steatosis and inflammation scores (Fig. 5D). As expected, ALA
decreased perirenal fat weight (Table 1). All the serum variables
obtained for ALA-fed mice were significantly lower compared with
the HFD-fed group (Table 1, Pb.05). Plasma glucose was significantly
different in these groups (Table 1, Pb.05).
These data showed that the weight of ALA-controlled mice was
reflected by improved hepatic lipid metabolism and decreased
triacylglycerol accumulation in vivo.Fig. 6. Proposed scheme illustrating the role of ALA in the regulation of hepatocyte lipid
metabolism and antioxidation. ALA reverses the HFD-induced changes in AMPK
expression, which is involved in SIRT1/LKB1/AMPK-mediated signaling, and transcrip-
tion factors FoxO1, SREBP-1 and nuclear Nrf2 protein expression, along with changes in
the lipid metabolism and antioxidative enzyme expression.ALA-fed mice showed increased SIRT1, p-AMPK, p-ACC, p-SREBP-
1and ATGL production and decreased p-FoxO1 and FAS expression
(Fig. 5E).
4. Discussion
Hepatic steatosis is characterized by obesity and dysregulated
lipid metabolism, including increased de novo lipogenesis or de-
creased lipolysis [32]. The present study aimed to determine the
mechanism underlying the ALA-mediated activation of the transcrip-
tion factors SREBP-1, FoxO1 and Nrf2 for hepatic steatosis prevention,
in vivo or in vitro.
Mounting evidence suggests that SIRT1 and AMPK are two critical
signaling targets controlling the pathways of hepatic lipid metabo-
lism. In the present study, we showed that ALA increases SIRT1
deacetylase activity, LKB1 deacetylation and AMPK activity in HepG2
cells (Fig. 6). ALA substantially prevents the impairment of lipid
accumulation due to elevated phosphorylation of AMPK and ACC
when HepG2 cells were exposed to palmitate. The effects of ALA were
largely abolished by pharmacological and genetic inhibition of SIRT1,
suggesting that the stimulation of AMPK and lipid-lowering effect of
ALA depends on SIRT1 activity.
Furthermore, expression of SIRT1 and p-AMPK is stimulated by
ALA in themouse liver. AMPK activation by SIRT1 also protects against
FAS production and lipid accumulation in HFD-fed mice. Our data
suggest that SIRT1 is a crucial target of ALA in hepatic metabolism.
ALA alleviates hepatic steatosis by coordinating multiple lipid
metabolism signaling pathways, which in turn boost the oxidation
of hepatic fatty acids and reduce hepatic lipogenesis in HFD-fed mice.
As far as we know, this is the first study to demonstrate the synergy of
ALA in regulating oxidative stress and improving lipid metabolism in
liver cells.
The role of SIRT1 in lipid metabolism is being established in
connection with FoxO1-mediated ATGL expression [29]. According
to previous studies, transgenic mice overexpressing SIRT1 dis-
played significant decreases in total blood cholesterol and white
adipose tissue, and it was proposed that deleted in breast cancer-1
(DBC1) induced SIRT1 regulation and contributed to HFD-induced
liver steatosis in mice [33,34]. In cultured adipocytes, knockdown
of SIRT1 decreased TG hydrolysis by reducing ATGL expression,
following elevated levels of acetylated and phosphorylated FoxO1
[29]. Taken together, these studies agree with our results and
indicate that the lipid-lowering effects of ALA are mediated by the
SIRT1/LKB1/AMPK pathway to activate FoxO1/ATGL signaling. In
addition to the effects on lipid catabolism, ALA may alternatively
modulate lipid anabolism via SREBP-1/FAS (Fig. 6). We showed
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reduced nuclear translocation of SREBP-1. Activated AMPK report-
edly suppressed the proteolytic cleavage and nuclear translocation
of SREBP-1 via direct phosphorylation in hepatocytes, ultimately
decreasing the plasma levels of TC and TG. SREBP-1 is known as
the sterol regulatory element 1 (SRE-1) and contains regulatory
elements in the promoter of low density lipoprotein receptor and
3-hydroxy-3-methylglutaryl-coenzyme A synthase (HMG-CoA
synthase) genes, similar to the FAS gene [35]. SREBP-1 induces
the basic transcription of these genes in the hamster liver [36].
Therefore, the decrease of the active SREBP-1 form probably
reduces the production of cholesterol and fatty acids. This evidence
supports our findings that ALA exerts lipid-lowering effects by
activating SIRT1/LKB1/AMPK/SREBP-1 signaling.
One of the most important antioxidant mechanisms is mediated
by the transcription factor Nrf2. Briefly, Keap1 binds to actin
cytoskeleton and Nrf2 to retain Nrf2 in the cytoplasm under basal
conditions. Upon exposure of cells to oxidative stress or chemopre-
ventive compounds, Nrf2 dissociates from Keap1, translocates to the
nucleus, forms a heterodimer with its obligatory partner Maf, and
ultimately activates ARE-dependent gene expression. Nrf2/ARE
signaling is also known to be primarily responsible for the up-
regulation of antioxidant gene expression and hence constitutes a
crucial cellular response to environmental stresses [37]. As expected,
ALA increased both Nrf2 and HO-1/SOD2 expression regardless of
stress [38]. Reports have recently demonstrated a regulatory role for
SIRT1 in the Nrf2/ARE antioxidant pathway [14,39]. Indeed, it was
suggested that indole-3-carbinol's protective action against hepatic
steatosis is at least partially mediated through the up-regulation of
SIRT1-AMPK signaling in the livers of HFD-fedmice [24]. In this study,
we also found that ALA significantly activated Nrf2/ARE signaling.
Enhancing the SIRT1 function by resveratrol and SIRT1 overexpres-
sion significantly promoted the nuclear accumulation, DNA binding
and transcriptional activities of Nrf2, evidently up-regulated HO-1
and SOD levels and eventually diminished AGE-induced ROS
production. Increasing SIRT1 levels in in vivo and in vitro models
promoted resistance to diabetic renal fibrosis by activating Nrf2,
similar to known Nrf2 activators, such as sulforaphane and cinnamic
aldehyde [40]. It is also known that HO-1 induction mediates the
antiapoptotic effect of AMPK, providing an important adaptive
response to preserve endothelial cell viability during metabolic stress
[41]. Interestingly, it was shown that ALA may alleviate lipopolysac-
charide-induced acute lung injury through HO-1 induction, which in
turn suppresses NF-κB-mediated inflammatory responses [42]. Our
data suggested that ALA increases the interaction between SIRT1 and
Nrf2 (Fig. 6). The impact of the interplay between these proteins on
the activation of the Nrf2/ARE pathway requires further investigation.
Encouragingly, we have conducted a study to evaluate the role of ALA
in improving the fatty liver in HFD-induced obese mice. Interestingly,
ALA at 100 mg/kg/day significantly reduced body weight and fat
mass, and increased the fatty acid oxidation in the liver. Thus, both the
in vitro and in vivo studies suggest a potential benefit for ALA as an
anti-NAFLD agent.
Taken together, our results demonstrated that ALA reduces lipid
accumulation in the liver by regulating the transcriptional factors
SREBP-1, FoxO1, and Nrf2, and their downstream lipogenic targets via
the activation of the SIRT1/LKB1/AMPK pathway. The present study
reveals the promising role of ALA in the prevention and treatment of
hepatic steatosis, in vivo and in vitro.References
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